
    
      Patients will be randomized equally between the four arms.

        1. Control group (placebo, two-week interval): 38 subjects

        2. Study group 1 (GV1001 0.4 mg, intradermal administration, two-week interval): 38
           subjects

        3. Study group 2 (GV1001 0.56 mg, intradermal administration, two-week interval): 38
           subjects

        4. Study group 3 (GV1001 0.56 mg, intradermal administration, four-week interval): 38
           subjects
    
  